March 19, 2018 by Chain Drug Review
Amazon, beauty care, CVS Pharmacy, drug channel, drug stores, Forever 21, Glowhaus, Jefferies, Jordan Rost, Kylie Cosmetics, Larissa Jensen, mass beauty care, mass market beauty sales, mass retailers, Mintel, Nielsen, NPD Group, Riley Rose, Sarah Jindal, Sephora, Steph Wissink, Target, Ulta Beauty, Walgreens, Walmart
2018, Business, Featured Articles, Issue 03-19-2018, Issues, Leading Headlines, News, Retail News

NEW YORK — It is a pivotal juncture for the beauty care category in the drug channel. Retailers and brands need to devise a game plan to wrest the business away from prestige power players. Sales in cosmetics, skin care and grooming are firing on all cylinders — but sadly, not in the mass beauty
February 8, 2018 by Chain Drug Review
Bob Sanders, Brian Tanquilut, Flu Fury: IRI Pinpoints How Flu Is Impacting U.S. Markets, IRI, IRI Flu Fury, IRI Illness Tracking, IRI's Health Care Practice, Jefferies, spread of the flu, Susan Viamari, Walgreens Flu Index
Business, Leading Headlines, Retail News

NEW YORK — The escalating number of flu cases nationwide has hoisted sales of over-the-counter medicines and other products that help treat and manage flu symptoms, according to market research firm IRI. In a new report titled “Flu Fury: IRI Pinpoints How Flu Is Impacting U.S. Markets,” IRI spotlights areas hit hard by the spread
December 14, 2017 by CDR Blog and Chain Drug Review
Amazon, Brian Tanquilut, CVS-Aetna merger, FedEx, Jefferies, Walgreens Boots Alliance
CDR Blog

A CVS-Aetna merger or not, Walgreens Boots Alliance is zeroed in and making headway on its strategic game plan, according to Jefferies analyst Brian Tanquilut. Following a visit to WBA’s headquarters in Deerfield, Ill., last week by the Jefferies team, Tanquilut reported that the CVS deal didn’t “prompt a kneejerk reaction,” and WBA executives remain
December 11, 2017 by Bill Schiffner
Aetna, Amazon, Brian Tanquilut, CVS Health, CVS Pharmacy, CVS-Aetna merger, Jefferies, Larry Merlo, Mark Bertolini, MinuteClinic
2017, Issue 12-11-2017, Issues, News

WOONSOCKET, R.I. — CVS Health plans to acquire health insurer Aetna for roughly $69 billion in a first-of-its kind deal aimed at fending off challenges in retail and health care. The landmark CVS-Aetna merger deal comes at time when insurers are under pressure to lower medical costs, and retailers are under attack from new competitors,
October 30, 2017 by Chain Drug Review
Amazon, Amazon pharmacy market entry, Amazon's medical equipment sales, Brian Tanquilut, drug retailing, Jefferies
Business, Leading Headlines, Pharmacy, Retail News

NEW YORK — Fears among pharmacy players and investors that e-tail giant Amazon plans to enter the industry may be overblown — at least for the time being, according to Jefferies analyst Brian Tanquilut. Pharmacy stocks, including pharmacy retailers and suppliers, have taken a pounding since the St. Louis Post-Dispatch reported last week that Amazon
October 26, 2017 by CDR Blog and Chain Drug Review
Aetna, Amazon, Brian Tanquilut, CVS Health, CVS-Aetna deal, Jefferies
CDR Blog, Featured Articles, Leading Headlines

Published reports said Thursday that CVS Health is in negotiations to acquire health insurer Aetna. CVS reportedly will offer more than $200 share, or about $66 billion, to purchase the health benefits giant, according to anonymous sources cited by the Wall Street Journal, which originated the story about a potential CVS-Aetna deal. Bloomberg reported that
July 5, 2017 by Chain Drug Review
Brian Tanquilut, Fitch Ratings, Jefferies, Rite Aid, Scot Mushkin, Stefano Pessina, Walgreens Boots Alliance, Wolfe Research
Business, Featured Articles, Leading Headlines, Retail News

DEERFIELD, Ill. — Analysts said Walgreens Boots Alliance turned in a solid third quarter and stands to emerge on a positive note from its new deal with Rite Aid Corp. upon the termination of their merger. For the third quarter ended May 31, WBA posted net earnings (GAAP) of $1.16 billion, or $1.07 per diluted
June 16, 2017 by Geoff Walden and Chain Drug Review
Amazon.com, Christopher Mandeville, Jeff Bezos, Jefferies, John Mackey, Whole Foods Market
Business, Featured Articles, Leading Headlines, Retail News

SEATTLE — Amazon.com Inc. will acquire Whole Foods Market Inc. for $13.7 billion, including debt, in the biggest deal ever for the e-tailer as it continues to encroach on the grocery sector. Amazon will pay $42 a share in cash for the natural food chain, the companies said Friday. Whole Foods cofounder and chief executive
December 23, 2016 by CDR Blog and Chain Drug Review
Brian Tanquilut, Fred's, Jefferies, Mike Bloom, Rite Aid, Walgreens Boots Alliance, Walgreens-Rite Aid merger
CDR Blog

Though Fred’s name came up in the buzz surrounding the Walgreens-Rite Aid merger talks with the FTC, the Southeastern retailer’s move to buy 865 Rite Aid stores for $950 million in cash from Walgreens Boots Alliance (WBA) still was surprising. After all, not even two weeks ago, Fred’s reported poor third-quarter results (including a net
December 15, 2016 by Chain Drug Review
Brian Tanquilut, CVS Analyst Day, CVS Health, Dave Denton, Jefferies, Larry Merlo, PBM market, Walgreens Boots Alliance, Walgreens-Rite Aid merger
Business, Featured Articles, Leading Headlines, Retail News

NEW YORK — CVS Health’s integrated pharmacy care model makes it a “partner of choice” in the health care arena, president and chief executive officer Larry Merlo said at the company’s annual Analyst Day event in Manhattan. Merlo and senior CVS Health executives gathered in New York on Thursday to give the investment community an
June 16, 2016 by Chain Drug Review
EnvisionRx, Jefferies, John Standley, Mark Wiltamuth, Rite Aid, Walgreens Boots Alliance, WBA-Rite Aid merger
Business, Featured Articles, Leading Headlines, Retail News

CAMP HILL, Pa. — Rite Aid Corp. cited pressure in pharmacy reimbursement as it reported a net loss and fell short of Wall Street’s earnings forecast for its fiscal 2017 first quarter. Meanwhile, overall retail sales and same-store sales edged up for the quarter, and the EnvisionRx pharmacy benefit management business, acquired about a year